T
CRSP icon

Transce3nd’s CRISPR Therapeutics CRSP Stock Holding History

Transce3nd’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2
Closed -$97 – 349
2025
Q2 		$97 Hold
2
– – ﹤0.01% 1188
2025
Q1 		$68 Hold
2
– – ﹤0.01% 1168
2024
Q4 		$79 Buy
+2
New +$94 ﹤0.01% 1523

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Transce3nd's CRSP Position: Q3 2025 in Review

Transce3nd sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 2 shares — an estimated $97 sold.

Transce3nd first reported a position in CRSP in Q4 2024 and held it in 3 quarters. The position peaked at $97 in Q2 2025. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

  • Transce3nd reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Transce3nd sold 2 CRISPR Therapeutics shares in Q3 2025, an estimated $97.
  • Transce3nd first reported a position in CRISPR Therapeutics in Q4 2024 and held it in 3 quarters.
  • Transce3nd's CRISPR Therapeutics position peaked at $97 in Q2 2025.
  • 440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on Transce3nd's 13F filing for Q3 2025, filed 12 Nov 2025.